Meet the 2 Formerly Down-and-Out Stocks That Are Outperforming the S&P 500 This Year. Are They Still a Buy?

Moderna (MRNA) has rallied ~70% year-to-date after reaffirming up to 10% revenue growth and repositioning toward seasonal vaccines, oncology and rare diseases (its vaccine business peaked at >$18B in 2022 after a ~90% drop through end-2025). Target (TGT) is up >20% YTD as CEO Michael Fiddelke executes a multi-year turnaround including a $2B investment this year; Target trades at ~14x forward earnings vs. peers >40x. The piece highlights a broader investor rotation from AI into defensive healthcare and retail amid geopolitical concerns (Iran), suggesting continued investor preference for revenue stability over high-growth tech for now.

Analysis

A meaningful reallocation of marginal risk capital toward businesses perceived as necessity-exposure has altered the liquidity topology: bid depth in defensives has compressed implied volatility and raised prices for names with predictable revenue streams, while leaving growth/AI beta vulnerable to speed bumps. That shift creates second-order winners beyond the headline stocks — contract manufacturers, specialty logistics and cold-chain providers, packaging suppliers, and niche retail brands that benefit from improved shelf placement and order cadence as retailers rework assortments.

Key catalysts to watch are calendared, binary events and cash-flow sequencing rather than broad macro headlines: regulatory verdicts and product approvals can re-accelerate revenue trajectories within quarters, while inventory rebalancing and margin catch-up from trade-spend or labor investments will show up more gradually across 2–6 quarters. Tail risks that would reverse the trade include a rapid risk-on return to growth/AI (reflowing liquidity out of defensives in 4–8 weeks), an unexpected demand shock from faster-than-expected rate-driven retail weakness, or an adverse regulatory outcome for a biotech program — any of which could wipe out recent multiple expansion quickly.

For portfolios, the current environment favors asymmetric structures that let you participate in mean-reversion to defensive narratives but limit single-stock downside. Relative-value exposure (long stabilized revenue streams funded by shorting concentrated growth beta) and calendarized option structures around known catalysts offer the best risk-adjusted paths. Position sizing should be modestly pro-cyclical: treat these as tactical exposures (2–4% notional per idea) with explicit stop rules tied to catalyst windows.

Key Decisions for Investors

• Long MRNA through a 9–12 month call-spread (buy 1x 9–12m OTM call, sell 1x higher strike call to finance). Size ~2–3% notional. Rationale: buy optionality on a re-acceleration narrative while capping premium; target asymmetric 40–100% upside if regulatory/seasonal catalysts print, capped downside = premium (~100% loss of premium). Close or reassess at the first post-catalyst quarter report.
• Long TGT shares with a financed collar: buy shares (~2–3% notional), buy a 6-month 10% OTM put and finance by selling 1–3 month slightly OTM calls. Rationale: capture execution-led upside with downside protection; expected target return 20–30% over 6–12 months if comp/margin improvements persist, downside limited to ~10% before put kicks in.
• Relative trade: long TGT vs short NVDA futures/options (3–6 month horizon), equal dollar exposure to neutralize market beta. Rationale: expresses rotation from high-beta AI exposure into defensive retail; reward accrues if flows continue to reprice defensives up while growth beta cools. Risk: a rapid tech-led rally can produce sharp mark-to-market losses—use strict stop at 8–10% adverse move.
• Portfolio hedge: buy short-dated (1–3 month) puts on NVDA or GOOGL sized to cover 3–5% portfolio exposure. Rationale: protects against a swift risk-off reversal that would simultaneously hit growth names and pressure the relative trades; cost is small insurance premium vs concentrated downside risk.